These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

360 related articles for article (PubMed ID: 22002076)

  • 1. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
    Guo C; Pirozzi CJ; Lopez GY; Yan H
    Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
    Han CH; Batchelor TT
    Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH mutations in glioma and acute myeloid leukemia.
    Dang L; Jin S; Su SM
    Trends Mol Med; 2010 Sep; 16(9):387-97. PubMed ID: 20692206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
    Weller M; Wick W; von Deimling A
    Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.
    Ohba S; Hirose Y
    Neurol Med Chir (Tokyo); 2016; 56(4):170-9. PubMed ID: 26960449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel inactivating mutation in Isocitrate Dehydrogenase 1 (IDH1-R314C) in a high grade astrocytoma.
    van Lith SA; Navis AC; Lenting K; Verrijp K; Schepens JT; Hendriks WJ; Schubert NA; Venselaar H; Wevers RA; van Rooij A; Wesseling P; Molenaar RJ; van Noorden CJ; Pusch S; Tops B; Leenders WP
    Sci Rep; 2016 Jul; 6():30486. PubMed ID: 27460417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-hydroxyglutarate production, but not dominant negative function, is conferred by glioma-derived NADP-dependent isocitrate dehydrogenase mutations.
    Jin G; Reitman ZJ; Spasojevic I; Batinic-Haberle I; Yang J; Schmidt-Kittler O; Bigner DD; Yan H
    PLoS One; 2011 Feb; 6(2):e16812. PubMed ID: 21326614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glioma-derived mutations in IDH: from mechanism to potential therapy.
    Fu Y; Huang R; Du J; Yang R; An N; Liang A
    Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
    Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
    J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Isocitrate dehydrogenase mutations may be a protective mechanism in glioma patients.
    Zhu J; Zuo J; Xu Q; Wang X; Wang Z; Zhou D
    Med Hypotheses; 2011 Apr; 76(4):602-3. PubMed ID: 21284999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.
    Zhang C; Moore LM; Li X; Yung WK; Zhang W
    Neuro Oncol; 2013 Sep; 15(9):1114-26. PubMed ID: 23877318
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural studies of Saccharomyces cerevesiae mitochondrial NADP-dependent isocitrate dehydrogenase in different enzymatic states reveal substantial conformational changes during the catalytic reaction.
    Peng Y; Zhong C; Huang W; Ding J
    Protein Sci; 2008 Sep; 17(9):1542-54. PubMed ID: 18552125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metabolism, gliomas, and IDH1.
    Smeitink J
    N Engl J Med; 2010 Mar; 362(12):1144-5. PubMed ID: 20335593
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
    Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
    Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
    Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
    J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDH1 and IDH2 mutations in gliomas.
    Cohen AL; Holmen SL; Colman H
    Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.